Dernières nouvelles pour Nuwellis (NASDAQ:NUWE) Stock

Nuwellis

Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.

Nuwellis Inc

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Highlights from the presentation: The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
Results of DEXA scan assessments of body composition in older subjects with obesity: At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.

Biotech

News

General

VERU

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

Monness, Crespi, Hardt analyst Gus Gala downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

Monness, Crespi, Hardt Downgrades Marqeta to Neutral

Barclays analyst Andrew Mok maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $405 to $420.

Price Target

Barclays Maintains Overweight on Cigna, Raises Price Target to $420

Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) shares are trading higher after its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740316/marathon-petroleum-corp-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results</a>.
Total revenues and other income of&nbsp;$35.4 billion&nbsp;topped the consensus of&nbsp;$32.8 billion.
Adjusted EBITDA was&nbsp;$2.49 billion&nbsp;for the quarter, compared with&nbsp;$5.71 billion in prior year quarter. Refining operating costs per barrel were&nbsp;$5.30&nbsp;versus&nbsp;$5.14&nbsp;a year ago.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41725310/marathon-petroleum-q3-earnings-preview-can-strong-sales-volume-offset-rising-costs" rel="noreferrer noopener">Marathon Petroleum Q3 Earnings Preview: Can Strong Sales Volume Offset Rising Costs?</a>
Refining &amp; Marketing refined product sales volume for the quarter was 3,685 mbpd&nbsp;(vs. 3,596 mbpd a year ago); Crude oil capacity utilization was&nbsp;94% (flat year over year).&nbsp;&nbsp;
Refining&nbsp;&amp; Marketing segment adjusted EBITDA declined to&nbsp;$1.053 billion from&nbsp;$4.373 billion a year ago due to lower market crack spreads.
Adjusted EPS for the quarter was&nbsp;$1.87,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">above the consensus of&nbsp;$0.98</a>.
As of September-end, Marathon Petroleum had&nbsp;$5.1&nbsp;billion&nbsp;of&nbsp;cash, cash equivalents,&nbsp;and&nbsp;short-term investments and&nbsp;$5 billion&nbsp;available&nbsp;on&nbsp;its bank revolving credit facility.
In the&nbsp;third quarter, the company returned around&nbsp;$3.0&nbsp;billion&nbsp;to shareholders, including&nbsp;$2.7&nbsp;billion&nbsp;in share repurchases and&nbsp;$273&nbsp;million&nbsp;in dividends. Through&nbsp;October 31, the company bought back an additional&nbsp;$0.5 billion&nbsp;of shares.
Additionally, the company&#8217;s board approved an incremental&nbsp;$5 billion&nbsp;share repurchase authorization. With the addition of this new authorization, Marathon Petroleum has&nbsp;$8.5 billion&nbsp;available under its share repurchase authorizations.&nbsp;
On&nbsp;October 30, the company increased its quarterly dividend to&nbsp;$0.91&nbsp;per share. The dividend is payable&nbsp;on December 10 to shareholders of record on&nbsp;November 20.&nbsp;&nbsp;&nbsp;
Outlook: Marathon Petroleum expects&nbsp;fourth-quarter Refining operating costs per barrel of&nbsp;$5.50 and&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Refinery throughputs of 2,880 mbpd</a>.&nbsp;
Marathon Petroleum owns the general partner and majority limited partner interest in&nbsp;MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>), which reported&nbsp;third-quarter earnings per limited partner unit of&nbsp;$1.01, missing the consensus of&nbsp;$1.07, and revenues&nbsp;of&nbsp;$2.97 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740434/mplx-lp-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the consensus of&nbsp;$3.09 billion</a>.&nbsp;MPLX returned&nbsp;$949 million of capital to unitholders in the quarter.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) and&nbsp;VanEck Oil Refiners ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRAK#NYSE">CRAK</a>).
Price Action: MPC shares are up 2.80% at $149.00 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41295799/3-midstream-stocks-poised-to-benefit-as-geopolitical-tensions-rise" target="_blank" rel="noreferrer noopener">3 Midstream Stocks Poised to Benefit as Geopolitical Tensions Rise</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

CRAK

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

MPLX

Marathon Petroleum Q3 Earnings: Outpaces Expectations, Powers Up Shareholder Rewards & More

WIIM

LIND

Lindblad Expeditions shares are trading higher after the company reported better-than-expected Q3 financial results.

DLTR

Dollar Tree shares are trading higher after JP Morgan maintained a Neutral rating on the stock an raised its price target from $70 to $82.

HDSN

Hudson Technologies shares are trading lower after the company reported worse-than-expected Q3 revenue results and Canaccord Genuity cut its price target on the stock from $8.75 to $8.

SPPL

Simpple Ltd shares are trading higher after the company announced its plan to regain NASDAQ compliance.

The Board of Directors approved an incremental $5 billion share repurchase authorization. With the addition of this new authorization, the company has $8.5 billion available under its share repurchase authorizations.&nbsp;

Marathon Petroleum Approved Incremental $5B Stock Buyback Authorization

Management

ADIL

Adial Pharmaceuticals Appoints Vinay Shah As Chief Financial Officer, Effective Nov. 16

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.verint.com%2F&amp;esheet=54147052&amp;newsitemid=20241105841152&amp;lan=en-US&amp;anchor=Verint%26%23174%3B&amp;index=1&amp;md5=cd382155b60eff877615bca4ef844957">Verint&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>), The CX Automation Company&#x2122;, today announced that a leading bank awarded Verint an $11 million contract for its AI-powered Agent Copilot Bot to assist 6,500 agents in their contact center.&#x2A;
The bank's contact center agents speak with customers for approximately 400 million minutes each year. The Verint AI-powered bot is designed to listen to these calls in the background and provide agents with real-time assistance, including coaching and guidance.
The bank conducted a pilot before awarding the contract and, based on the pilot result, the estimated annual savings from deploying the AI-powered bot is in the tens of millions of dollars.

Contracts

VRNT

Leading Bank Awards Verint $11M Contract For AI-Powered Agent Copilot Bot To Assist 6,500 Agents In Their Contact Center

BEAM

Beam Therapeutics shares are trading lower in reaction to a report indicating a patient in the company's CRISPR-based sickle cell treatment trial died.

SIMPPLE Outlines Plan To Regain Nasdaq Compliance, Including Potential Reverse Stock Split; Requests Hearing With Nasdaq To Seek Extension While Continuing Business Operations And Securing New Contracts

SI-BONE, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>), a&nbsp;Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite&#x2122; (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology like Granite by providing an add-on payment to hospitals and ambulatory surgery centers supporting it.
As part of the TPT determination, CMS confirmed that a customary deduction from the add-on payment, known as a device offset, will not be applied to lumbar spinal fusion procedures involving pelvic fixation with Granite. This decision recognizes that Granite costs are not currently included in the existing facility payment amount for the procedures using this technology.

SIBN

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Payment System

Simpple Ltd, A Leading Technology Provider Announced Its Plan To Regain NASDAQ Compliance

BLDP

Ballard Power Systems Expects Revenue In 2024 To Be Weighted Towards Q4

The New York State Common Retirement Fund has significantly reduced its stake in Vistra Corp., according to a recent filing with the Securities &amp; Exchange Commission (SEC). This move was executed during the third quarter.
What Happened: The fund divested 43,440 shares, marking a 21.6% reduction in its Vistra Corp. holdings. Following this transaction, the fund retains 157,565 shares of the company&#8217;s stock, valued at $18,678,000 as per the latest SEC filing. This adjustment is part of the fund&#8217;s broader portfolio management strategy.
The change in the portfolio comes at a time when Vistra Corp&#8217;s year-to-date (YTD) returns have crossed 200%. As per Benzinga Pro, Vistra Corp was trading 0.24% higher on Tuesday during pre-market than its previous day close at $115.74.
See Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early</a>
Why It Matters: Texas-based Vistra Corp. <a href="https://www.benzinga.com/insights/news/24/11/41715992/evaluating-vistra-against-peers-in-independent-power-and-renewable-electricity-producers-industry">stands as a major player</a> in the Independent Power and Renewable Electricity Producers industry. It is one of the largest power producers and retail energy providers in the U.S., especially after acquiring Energy Harbor in 2024. This acquisition expanded Vistra&#8217;s portfolio to include 41 gigawatts of nuclear, coal, natural gas, and solar power generation, alongside one of the world&#8217;s largest utility-scale battery projects.
Vistra&#8217;s retail electricity business serves approximately 5 million customers across 20 states, covering nearly a third of Texas&#8217;s electricity consumers. The company emerged as an independent entity in 2016 after the bankruptcy of Energy Future Holdings and further expanded by acquiring Dynegy in 2018.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41705665/palantir-technologies-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Palantir Technologies Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Top Analysts</a></li>
</ul>
Image via Midjourney
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Markets

New York State Common Retirement Fund Pares Vistra Corp Stake After Shares Rally Over 200% This Year

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOgSxpFF0XIvawVscW4wbdwg7V_FhA3Ltt3AEUAniLYFzGCWmQxbGtaOlCTeoy9z_gw==">https://heal.nih.gov</a>.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics,&nbsp;devices,&nbsp;or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOlGjlyIIOqxGCXGg7oAt6Z8k_ceVEneHLI1vwxQ_6cUhkiltyTw8QQT1pV5d70643HL2HPZdhRFfxJaV9YNhfRmH9nfw_RF6CKHtAfA4IrI-OAUc2GDix2f8AgJTeD-gGsZnWraYf9DQLl_KK0KyPERmmZ2qiTanbmibjkbPuCBhaatGJ8TqR2NK9mw7c9BFBPeEx1kzbGwZK3J_7R1YWB0=">https://heal.nih.gov/research/preclinical-translational/screening-platform</a>.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ARTL

Artelo Biosciences Announces Acceptance Of ART26.12 Into The National Institutes Of Health's Helping To End Addiction Long Term Initiative's Preclinical Screening Platform For Pain

MPLX shares are trading higher. The company reported Q3 financial results.

TCMD

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Nuwellis Q2 Earnings Preview

Nuwellis GAAP EPS of -$18.85 misses by $10.61, revenue of $2.19M beats by $0.19M

Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) just reported results for the second quarter of 2024.<ul><li>Nuwellis reported earnings per share of -$4.68. This was above the analyst estimate for EPS of -$8.24.</li><li>The company reported revenue of $2.19 million.</li><li>This was 9.70% better than the analyst estimate for revenue of $2.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nuwe-stock-earnings-nuwellis-for-q2-of-2024/">NUWE Stock Earnings: Nuwellis Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NUWE Stock Earnings: Nuwellis Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Anthony Vendetti maintained a Hold rating on Nuwellis (NUWE – Research Report) yesterday. The company's shares closed yesterday...

Maxim Group Keeps Their Hold Rating on Nuwellis (NUWE)

Nuwellis to sell 496,901 shares at $1.845 in registered direct offering

Nuwellis (NUWE) has issued an update. Nuwellis, Inc. has launched a financial venture, selling over 483,000 shares at $1.8450 each, alongside warra...

Nuwellis Secures Funds Through Shares and Warrants Offering

Nuwellis shares nearly doubled on higher than expected Q3 prelim revenue

Nuwellis (NUWE) announces that the Centers for Medicare and Medicaid Services, CMS, will reassign the Aquadex ultrafiltration code to the outpatien...

Nuwellis receives increased reimbursement rate for Aquadex SmartFlow therapy

AMBI

CERO

CGTX

CPTN

CREV

INVO

LGVN

LIPO

LUXH

NTBL

NUWE

NUWEW

PAPL

PHIO

TIVC

VCNX

VTVT

YIBO

Press Releases

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Health Care

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer

Economics

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Peraso Inc. (NASDAQ: PRSO) Volume Soars as SAF Tehnika Adopts Technology Across a $3.4B Market North America & Europe – More Stocks Inside!

Comments

Nuwellis

Actualités

Dernières nouvelles pour Nuwellis (NASDAQ:NUWE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL